今年夏季,絕不能錯過名勝壹號世界郵輪重回基隆啟航!多種優惠方案讓您輕鬆預訂心儀的日本沖繩郵輪行程,同時省下大筆開支!

The New Horizon Talks

1 年前
-
-
(基於 PinQueue 指標)
The New Horizon Talks
Welcome to The New Horizon Talks, a podcast series by CSL Behring. Hosted by Science Writer and Broadcaster Vivienne Parry, it explores issues surrounding cell and gene therapies and their promise to change the lives of people living with rare and serious diseases. With a European focus, each episode features leading experts, scientists, healthcare professionals, patients and patient representatives. Join the conversation on social media using #NewHorizonTalks.
Episode 6: Leveraging Real World Evidence for Advanced Therapy

This episode explores how real-world evidence is changing healthcare, its value in improving patients’ outcomes, its role in supporting R&D in advanced therapy and uptake of this innovation by health systems. It will discuss issues such as how to deal with evidence gaps in HTA and the role of RWE. It will reflect on the importance of the European Health Data Space in leveraging RWE collected in Europe and its benefits for rare disease patients. It will also look at how to ensure that health data is efficiently leveraged to help the development of advanced therapy in a sustainable, patient-centric, manner, patient engagement in data collection efforts and the role of clinicians. 

Guests: 

 Marcus Guardian (COO, EUnetHTA)

Prof. Marijke van den Berg (Director, European Paediatric Network for Haemophilia Management (PEDNET))

Thu, 27 Oct 2022 12:29:27 GMT
Episode 5: Advancing Europe's leadership in rare disease innovation

This episode explores the EU’s leadership in response to rare diseases and innovation in the area, with a special focus on advanced therapy research and development. What are the achievements made in Europe and where are the remaining gaps? How can Europe achieve leadership in innovation for rare diseases?

Guests: 

Yann Le Cam, CEO, EURORDIS

Elisabetta Zanon, Director, EU Public Affairs & Advocacy, Alliance for Regenerative Medicine, Europe

Tue, 20 Sep 2022 10:08:58 GMT
Episode 5: Advancing Europe’s leadership in rare disease innovation (Bonus edition)

This episode explores EU’s leadership in response to rare diseases and innovation in the area, with a special focus on advanced therapy research and development. What are the achievements made in Europe and where are the remaining gaps? How can Europe achieve leadership in innovation for rare diseases? The bonus edition provides insights about the impact of the COVID-19 pandemic on rare disease patients and innovation in the field.

Guests:

Yann Le Cam, CEO, EURORDIS

Elisabetta Zanon, Director, EU Public Affairs & Advocacy, Alliance for Regenerative Medicine, Europe

Thu, 11 Aug 2022 14:52:59 GMT
Episode 4: Taking the Ethical Debate Forward

This conversation takes a deep dive into the ethical issues surrounding cell and gene therapies. What are the main questions from patients and the broader public? What are the key myths surrounding these therapies? It explores topics such as transparency, responsibility in science and research efforts, inclusivity & non-discrimination in access.

Guest:

  • Hervé Chneiweiss, Chairman, INSERM Ethics Committee; Chair, UNESCO International Bioethics Committee; member, WHO Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing
Tue, 19 Oct 2021 12:48:50 GMT
Episode 3: Advancing For and With Patients

This podcast examines patient centricity in cell and gene therapy, exploring how care must be planned and delivered to be responsive to individual patient preferences, needs and values. What exactly does patient focus mean, when talking about advanced therapies? What should patients know before embarking on the therapy and how do patient advocacy organisations support patients in this process?

Guest:

· Durhane Wong-Rieger, Chair, Rare Disease International Council

----

Abbreviations:

· HTA: Health technology assessment

· ERNs: European reference networks

Wed, 06 Oct 2021 12:07:28 GMT
Episode 2: Transforming the Future of Healthcare Together

In this episode, we look at the unique policy challenges presented by cell and gene therapies from research & development through to patient access; and the role of multi-stakeholder collaborations, in particular those active in supporting European policymaking. How can we, together, deliver these innovative therapies to patients and society, efficiently and safely? 

Guests:

• Amanda Bok, Chief Executive, European Haemophilia Consortium (EHC)

• Alexander Natz, CEO, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)

----

Abbreviations:

• ATMPs: Advanced therapy medicinal products

• EBMT: European Society for Blood and Marrow Transplantation

• GBA: Gemeinsamer Bundesausschuss 

• HTA: Health technology assessment

• MEPs: members of European Parliament 

Mon, 27 Sep 2021 12:06:23 GMT
Episode 1: New Horizons for Rare Disease Patients

This episode provides an introduction to cell and gene therapies and touches upon the historical, scientific, clinical, policy and regulatory considerations surrounding their development and use, with forward-looking perspectives from our guests on the future of this new chapter of medicine.

Guests:

· Professor Luigi Naldini, Director, San Raffaele Telethon Institute for Gene Therapy

· Avril Daly, Vice-president, Rare Diseases Europe (EURORDIS); CEO, Retina International

----

Abbreviations:

· CAR T cells: chimeric antigen receptor T cells

· HTA: Health technology assessment

Wed, 22 Sep 2021 12:02:28 GMT
Bonus episode: Advancing For and With Patients

This podcast examines patient centricity in cell and gene therapy, exploring how care must be planned and delivered to be responsive to individual patient preferences, needs and values. What exactly does patient focus mean, when talking about advanced therapies? What should patients know before embarking on this therapy and how do patient advocacy organisations support patients in this process?

Guest:

• Durhane Wong-Rieger, Chair, Rare Disease International Council


Abbreviations:

· HTA: Health Technology Assessment

· ERNs: European Reference Networks

Fri, 27 Aug 2021 08:56:13 GMT
-
-
(基於 PinQueue 指標)
0 則留言